SeaCrest Wealth Management LLC purchased a new position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,125 shares of the company’s stock, valued at approximately $32,000.
Other hedge funds have also made changes to their positions in the company. Zions Bancorporation N.A. acquired a new stake in shares of Maravai LifeSciences during the first quarter worth about $28,000. Steward Partners Investment Advisory LLC raised its holdings in Maravai LifeSciences by 6,670.0% in the second quarter. Steward Partners Investment Advisory LLC now owns 1,354 shares of the company’s stock valued at $38,000 after acquiring an additional 1,334 shares in the last quarter. Van ECK Associates Corp acquired a new stake in Maravai LifeSciences in the second quarter valued at approximately $81,000. Point72 Hong Kong Ltd acquired a new stake in Maravai LifeSciences in the first quarter valued at approximately $163,000. Finally, Parametrica Management Ltd acquired a new stake in Maravai LifeSciences in the first quarter valued at approximately $241,000. Institutional investors and hedge funds own 51.02% of the company’s stock.
Maravai LifeSciences Stock Up 1.4 %
MRVI stock opened at $14.35 on Wednesday. The company has a current ratio of 7.22, a quick ratio of 6.68 and a debt-to-equity ratio of 0.62. Maravai LifeSciences Holdings, Inc. has a twelve month low of $13.40 and a twelve month high of $46.29. The company’s 50 day moving average is $19.08 and its two-hundred day moving average is $24.55. The stock has a market cap of $3.66 billion, a P/E ratio of 8.02 and a beta of -0.23.
Wall Street Analyst Weigh In
Maravai LifeSciences Company Profile
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
- Get a free copy of the StockNews.com research report on Maravai LifeSciences (MRVI)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.